Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-{3-[(4-anilinoquinazolin-6-yl)amino]-3-oxopropyl}-L-cysteine is a synthetic small molecule derivative of 4-anilinoquinazoline. Quinazoline derivatives, including those with an anilino group at the 4-position and amino substitution at the 6-position, are well known as potent inhibitors of protein kinases such as the epidermal growth factor receptor (EGFR). Many compounds in this class have been developed and approved as anticancer drugs (e.g., gefitinib, erlotinib, afatinib). The specific compound here is structurally related to these kinase inhibitors and may act by inhibiting EGFR or other kinases. Some quinazoline derivatives have also shown antiviral activity against coronaviruses in preclinical studies[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-{3-[(4-anilinoquinazolin-6-yl)amino]-3-oxopropyl}-L-cysteine.